OM:OV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Oncology Venture A/S develops drugs for the treatment of cancer using drug-specific companion diagnostics.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Oncology Venture's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.8%

OV

2.9%

SE Biotechs

5.0%

SE Market


1 Year Return

-64.9%

OV

10.7%

SE Biotechs

10.9%

SE Market

Return vs Industry: OV underperformed the Swedish Biotechs industry which returned 10.7% over the past year.

Return vs Market: OV underperformed the Swedish Market which returned 10.9% over the past year.


Shareholder returns

OVIndustryMarket
7 Day-5.8%2.9%5.0%
30 Day-18.6%9.0%12.7%
90 Day-32.1%21.5%1.4%
1 Year-64.9%-64.9%11.5%10.7%12.5%10.9%
3 Yearn/a27.1%23.9%16.4%0.7%
5 Yearn/a80.3%68.7%36.4%9.5%

Price Volatility Vs. Market

How volatile is Oncology Venture's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Oncology Venture undervalued compared to its fair value and its price relative to the market?

1.18x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OV is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OV is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OV is good value based on its PB Ratio (1.2x) compared to the SE Biotechs industry average (6.2x).


Next Steps

Future Growth

How is Oncology Venture forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-56.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OV's revenue is expected to decline over the next 3 years (-19.7% per year).

High Growth Revenue: OV's revenue is forecast to decline over the next 3 years (-19.7% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Oncology Venture performed over the past 5 years?

-51.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OV is currently unprofitable.

Growing Profit Margin: OV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OV is unprofitable, and losses have increased over the past 5 years at a rate of -51.4% per year.

Accelerating Growth: Unable to compare OV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: OV has a negative Return on Equity (-104.37%), as it is currently unprofitable.


Next Steps

Financial Health

How is Oncology Venture's financial position?


Financial Position Analysis

Short Term Liabilities: OV's short term assets (DKK10.8M) do not cover its short term liabilities (DKK27.2M).

Long Term Liabilities: OV's short term assets (DKK10.8M) exceed its long term liabilities (DKK8.2M).


Debt to Equity History and Analysis

Debt Level: OV's debt to equity ratio (0.02%) is considered satisfactory.

Reducing Debt: OV's debt to equity ratio has reduced from 0.2% to 0.02% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OV has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: OV is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Oncology Venture's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OV's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Steve Carchedi (57yo)

0.75

Tenure

Mr. Stefano R. Carchedi, also known as Steve, has been the Chief Executive Officer and President of ApeX Therapeutics, Inc. since October 2016. Mr. Carchedi serves as Chief Executive Officer and Director a ...


Leadership Team

NamePositionTenureCompensationOwnership
Peter Jensen
Co-Founder and Chairman of Medical & Scientific Advisory Board0.75yrø1.17mno data
Steen Knudsen
Founder16.42yrsno data4.62% DKK8.9m
Ulla Buhl
Founderno datano datano data
Stefano Carchedi
CEO, President & Director0.75yrno datano data
Claus Pedersen
Chief Commercial Officer2.33yrsno datano data
Henrik Moltke
Chief Financial Officer0.67yrno datano data
Thomas Jensen
Chief Technology Officer4.42yrsno datano data
James Cullem
Senior Vice President of Corporate Development1.42yrsno datano data
Annie Rasmussen
Chief of Clinical Operationsno datano datano data
Marie Foegh
Chief Medical Officer1.42yrsno datano data

1.4yrs

Average Tenure

57.5yo

Average Age

Experienced Management: OV's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Peter Jensen
Co-Founder and Chairman of Medical & Scientific Advisory Board0.75yrø1.17mno data
Steen Knudsen
Founder16.42yrsno data4.62% DKK8.9m
Stefano Carchedi
CEO, President & Director0.75yrno datano data
Daniel Von Hoff
Member of Scientific Advisory Boardno datano datano data
Gunnar Magnus Severus Persson
Director6.42yrsno datano data
Frank Knudsen
Deputy Chairmanno datano data0.0060% DKK11.5k
Joyce O'Shaughnessy
Member of Scientific Advisory Boardno datano datano data
Duncan Moore
Independent Chairman5.42yrsø127.47k0.20% DKK375.3k
Carani Sanjeevi
Independent Director5.42yrsø63.74kno data
Ursula Matulonis
Member of Scientific Advisory Boardno datano datano data

5.4yrs

Average Tenure

60.5yo

Average Age

Experienced Board: OV's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 165.1%.


Top Shareholders

Company Information

Oncology Venture A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncology Venture A/S
  • Ticker: OV
  • Exchange: OM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr192.304m
  • Shares outstanding: 133.54m
  • Website: https://www.oncologyventure.com

Number of Employees


Location

  • Oncology Venture A/S
  • Venlighedsvej 1
  • Horsholm
  • Capital Region of Denmark
  • 2970
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OVOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKAug 2018

Biography

Oncology Venture A/S develops drugs for the treatment of cancer using drug-specific companion diagnostics. Its product pipeline includes 2X-121, a PARP and tankyrase inhibitor in Phase II clinical trials for the treatment of ovarian cancer; Dovitinib, a pan-tyrosine kinase inhibitor in post-Phase III clinical trials for treatment renal cell carcinoma; and IXEMPRA, a microtublin inhibitor for treatment of metastatic breast cancer. The company is also developing LiPlaCis, a liposomal formulation of cisplatin in Phase II clinical trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin in Phase II clinical trials in breast cancer; and Irofulven, a DNA damaging agent in Phase II clinical trials for prostate cancer. Oncology Venture A/S was founded in 2004 and is headquartered in Hørsholm, Denmark. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/04 11:29
End of Day Share Price2020/06/03 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.